Healthcare / Medical DevicesTel Aviv
$34.40
+2.40 (+7.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-8.1M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$33M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.9%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-14.1M · FCF $-12.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-14.1M | $-14.1M | $-8.8M | $1.4M | $-12.1M |
| EBITDA | $-13.5M | $-13.5M | $-8.1M | $2.0M | $-11.5M |
| EPS | — | — | -0.09 | 0.01 | -0.14 |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.02 | 0.02 | 0.01 |
| Current Ratio | 10.31 | 10.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.1M | $-12.1M | $-8.1M | $7.0M | $-10.7M |
| Returns | |||||
| ROE | -55.9% | -55.9% | -22.3% | 2.7% | -23.6% |
| Valuation | |||||
| P/E | — | — | — | 3880.00 | — |
| EV/EBITDA | — | — | — | 2119.17 | — |
| P/B | 130.95 | 130.95 | 85.02 | 78.57 | 44.50 |
| Growth & Yield | |||||
| EPS Growth | — | — | -1000.0% | 107.1% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.09 → n/d
Residual
+7.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.